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sensitized to Der p 23, and 11 patients were negative for all 
HDM MeDALL chip components. Seven sera were available 
for further testing, and 3 of them showed IgE reactivity to 
dot-blotted nDer p 1, and 2 reacted with high-molecular 
weight components (>100 kDa) in nitrocellulose-blotted 
HDM extract when tested with  125 I-labeled anti-IgE in a RAST-
based assay. The HDM extract-specific IgE levels of the 11 
patients were <3.9 kU/l.  Conclusions: Recombinant aller-
gen-based IgE serology is of great value when conventional 
IgE diagnostics fails. Der p 23 is an important HDM allergen, 
especially when major allergens are negative. Therefore, it 
would be desirable to have Der p 23 commercially available. 
Further research concerning the prevalence and clinical sig-
nificance of different HDM allergens is needed. 
 © 2016 S. Karger AG, Basel 
 Introduction 
 House dust mites (HDM), especially  Dermatophagoi-
des pteronyssinus,  are the most important perennial aller-
gen sources in central Europe and cause allergic rhinitis 
as well as allergic asthma  [1] . So far, more than 20 differ-
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 Abstract 
 Background:  Dermatophagoides pteronyssinus is one of the 
most important perennial allergen sources worldwide. Mo-
lecular diagnostics using the commercially available major 
allergens (Der p 1 and Der p 2) in combination with Der p 10 
do not detect house dust mite (HDM) sensitization in a num-
ber of cases when used alone. The objective was to evaluate 
the IgE reactivity profiles of these patients using an experi-
mental immunoassay biochip.  Methods:  Sera of HDM-aller-
gic patients (positive skin prick test, CAP class  ≥ 1 for allergen 
extract, and positive intranasal provocation) were tested for 
IgE antibodies against Der p 1, Der p 2, and Der p 10 by Im-
munoCAP fluorescence enzyme immunoassay. Negatively 
tested sera were examined by an experimental chip contain-
ing 13 microarrayed HDM allergens.  Results: Of 97 patients 
tested, 16 showed negative results to Der p 1, Der p 2, and 
Der p 10. MeDALL chip evaluation revealed 5 patients mono-
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ent allergens of  D. pteronyssinus have been described, 
with a strong variation in prevalence rates for the major 
allergens Der p 1 and Der p 2 in different countries  [2–5] . 
The third currently commercially available allergen com-
ponent Der p 10 also showed varying prevalence rates be-
ing responsible for a part of the cross-reactions to arthro-
pods and mollusks  [5, 6] .
 Molecular allergy diagnostics has become an impor-
tant tool in daily allergological routine in allergy centers 
but also in smaller facilities within the last decade. The 
knowledge about major and minor allergen components 
and their prevalence opened new possibilities in allergy 
diagnostics and therapy. This powerful tool can often ex-
plain the sometimes frustrating outcomes of immuno-
therapy in the past and helps to choose the right treat-
ment option (symptomatic vs. immunotherapy) for the 
individual patient. In comparison to immunotherapy 
against grass or birch pollen, immunotherapy against 
HDM shows considerably lower success rates  [7, 8] . One 
reason for this reduced therapeutic success might be the 
fact that most commercially available therapeutic agents 
for immunotherapy of HDM allergy are standardized to 
the major allergens Der p 1, Der p 2, and Der f 1  [9, 10] , 
thereby not matching for patients sensitized to other 
components. Up to now, more than 20 allergen compo-
nents of  D. pteronyssinus with a varying prevalence and 
importance for therapy have been described. Weghofer et 
al. [11] showed a high allergenic activity of Der p 23. This 
new allergen component is localized in the peritrophic 
matrix lining the midgut of  D. pteronyssinus and also the 
surface of fecal pellets. Due to its association with mite 
feces, it becomes airborne and respirable, which might be 
a reason for its impact on the development of HDM al-
lergy.
 The aim of the current study was to investigate retro-
spectively the value of recombinant allergen-based IgE 
serology using an experimental allergen chip (MeDALL 
chip) in HDM-allergic patients tested negative for the 
commercially available HDM components Der p 1, Der p 
2, and Der p 10  [12] . The results may identify components 
which can improve diagnostics and therapy of HDM al-
lergy in the future.
 Patients and Methods 
 Patient data were selected from the allergy database of the De-
partment of Otorhinolaryngology, and Head and Neck Surgery of 
the Ludwig Maximilians University in Munich where all relevant 
diagnostic results of patients are stored. The study was approved 
by the local ethics committee and the local data protection com-
missioner. All patients gave informed consent. The database was 
scanned for consecutive patients with a proven perennial allergy 
to HDM who presented at our institution between 2001 and 2010. 
The diagnosis of HDM allergy was based on the following selection 
criteria: (1) A positive skin prick test for  D. pteronyssinus. The skin 
prick test (ALK-Abelló, Wedel, Germany) was read after 20 min. 
(2) CAP class  ≥ 1 [ ≥ 0.35 kU A /l; ImmunoCAP fluorescence enzyme 
immunoassay (FEIA); Thermo Fisher Scientific, Freiburg, Germa-
ny] for the HDM  D. pteronyssinus . (3) Positive intranasal provoca-
tion with a standard provocation solution ( D. pteronyssinus ; ALK-
Abelló) according to guideline specifications  [13] (decrease in rhi-
nomanometry >40% at 150 Pa on the allergen-challenged side or 
symptom score >3, or decrease in rhinomanometry >20% at 150 
Pa on the allergen-challenged side in combination with a symptom 
score >2). The provocation solution contained 200,000 SQ units/
ml or 19.6 μg/ml Der p 1 [pers. notification Prof. Dr. E. Wüsten-
berg, ALK-Abelló]. (4) Availability of the patient’s serum at our 
allergy serum bank.
 Nasal symptoms were semiquantitatively assessed using four 
categories on the day of the first visit: (1) obstruction, (2) rhinor-
rhea, (3) sneezing, and (4) itching. Each symptom could be an-
swered between 0 and 3: 0 = no impairment, 1 = mild impairment, 
2 = moderate impairment, 3 = severe impairment.
 Fluorescence Enzyme Immunoassay  
 Sera of the patients which fulfilled the above-mentioned crite-
ria were analyzed for specific IgE antibodies to nDer p 1, rDer p 2, 
and rDer p 10 using the FEIA method with a commercial test kit 
(ImmunoCAP-FEIA, Thermo Fisher Scientific). Results were stat-
ed in CAP classes as well as in concentrations (kU/l).
 MeDALL Allergen Chip Analysis 
 Sera of patients with a negative result to nDer p 1, rDer p 2, and 
rDer p 10 were examined for specific IgE antibodies to cross-reac-
tive carbohydrate determinants (CCDs) and then transferred to 
ThermoFisher-Phadia multiplexing, Vienna, Austria, for MeDALL 
chip analysis.
 The MeDALL allergen chip is based on the latest allergen mi-
croarray technology for diagnosis and monitoring of IgE and IgG 
reactivity profiles of allergic patients which was developed within 
the FP 7-funded European Union project MeDALL in collabora-
tion with the Division of Immunopathology, Department of 
Pathophysiology and Allergy Research, Medical University of Vi-
enna, and ThermoFisher-Phadia multiplexing. Beside a broad va-
riety of different allergen groups, the chip contains a panel of 13 
components from  D. pteronyssinus (Der p 1, Der p 2, Der p 4, Der 
p 5, Der p 7, Der p 11, Der p 14, Der p 15, Der p 18, Der p 21, and 
Der p 23) and clone 16-encoded allergen. Sera from patients fulfill-
ing the above-mentioned criteria were examined by the chip as 
described  [12] .
 Statistical Analysis 
 Statistical analysis was performed with SigmaStat and Sigma-
Plot 2000 for Windows version 6.00 (Jandel Corp., San Rafael, Ca-
lif., USA). To compare nasal symptoms, normally distributed data 
were tested by t test and given as means ± SD. To compare non-
normally distributed data, the Mann-Whitney rank sum test was 
used, and results are given as medians and ranges. To examine the 









 The database query with the above-mentioned inclu-
sion criteria resulted in 97 patients with a proven allergy 
to HDM. Prevalence rates for  D. pteronyssinus , nDer p 1, 
rDer p 2, and rDer p 10 were 100, 77, 74 and 4%, respec-
tively. IgE concentrations were 15.69 ± 21.33, 10.40 ± 
15.85, 17.63 ± 24.76 and 0.89 ± 0.80 kU/l (means ± SD) 
respectively. IgE levels to HDM extract  D. pteronyssinus 
correlated well with the sum of IgE levels of Der p 1, Der 
p 2 and Der p 10. Pearson’s correlation coefficient r = 
0.851, p < 0.05, n = 81. Sixteen patients showed negative 
results to all three components ( table 1 ;  fig. 1 ). Within this 
group, gender distribution showed 9 female (56%) and 7 
male (44%) patients with a mean age of 34.1 (14.7 SD) 
years and a range between 11 and 60 years. Nine patients 
(56%) showed a single sensitization to HDM, 7 patients 
(43%) showed additional sensitization to further aeroal-
lergens.
 MeDALL chip evaluation of these 16 sera tested posi-
tive to  D. pteronyssinus but negative to Der p 1, Der p 2, 
and Der p 10 resulted in 5 patients (31%) sensitized to Der 
p 23. All other HDM allergens on the chip (Der p 1, Der 
p 2, Der p 4, Der p 5, Der p 7, Der p 10, Der p 11, Der p 
14, Der p 15, Der p 18, and Der p 21, and clone 16) were 
negative. Negative test results were also seen for the two 
major allergen components of  D. farinae Der f 1 and Der 
f 2 in these 16 patients. Examination of specific IgE anti-
bodies to CCDs showed negative results in 12 patients, 2 
patients showed positive results (1 CAP class 2 and 1 CAP 
class 1). Both patients were polysensitized with high con-
centrations of specific IgE to birch, grass, and other plants. 
In 2 patients, there was no serum left for this examination. 
Detailed information about the 16 patients who under-
went MeDALL chip evaluation can be found in  table 2 . In 
 Table 1.  Patient demographics and study results
All patients, n (%) 97 (100)




Monosensitized to HDM, n (%) 30 (31)
Polysensitized, n (%) 61 (63)
No data available, n (%) 6 (6)
Nasal symptoms, means ± SD
Obstruction 1.95 ± 1.07
Rhinorrhea 1.41 ± 1.00
Sneezing 1.32 ± 0.96
Itching 1.12 ± 0.93
Nasal symptoms were semiquantitatively assessed on the day 








































































 Fig. 1.  a Prevalence of IgE reactivity to  D. pteronyssinus (D. pter.), nDer p 1, rDer p 2, and rDer p 10 in proven 
HDM-allergic patients in southern Bavaria (n = 97).  b Prevalence rates for different combinations of the two 
major allergens Der p 1 and Der p 2. Sixteen patients negative for the two allergen components had also negative 
results for Der p 10. Adapted from [4], with kind permission of Springer publishing house. 
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the 5 Der p 23-positive patients, specific IgE levels to 
HDM extract (measured in kU/l) and MeDALL chip re-
sults to Der p 23 (measured in ISAC standardized units) 
tend to increase together with Pearson’s correlation coef-
ficient r = 0.808. Unfortunately, correlation was not sig-
nificant (p = 0.084) due to the low number of patients
(n = 5). The symptoms of these patients did not differ 
from those of the entire cohort of 97 HDM-allergic pa-
tients [obstruction median 2.00 (range 0.00–3.00) vs. 2.00 
(0.00–3.00), p = 0.69; rhinorrhea 2.00 (0.00–2.00) vs. 1.00 
(0.00–3.00), p = 0.96; sneezing 1.00 (0.00–3.00) vs. 1.00 
(0.00–3.00), p = 0.99, and itching 1.00 (0.00–3.00) vs. 1.00 
(0.00–3.00), p = 0.93] nor did Der p 23-positive in com-
parison to Der p 23-negative patients [obstruction 2.00 ± 
1.16 (mean ± SD) vs. 1.88 ± 0.99, t(10) = 0.20, p = 0.85; 
rhinorrhea 2.00 (0.00–2.00) vs. 1.50 (0.00–2.00), p = 0.68; 
sneezing 1.00 ± 0.82 vs. 1.50 ± 1.07, t(10) = 0.82, p = 0.43, 
and itching: 1.25 ± 1.50 vs. 1.25 1.04, t(10) = 0.00, p = 
1.00].
 For the 11 sera which were tested negative for all aller-
gen components, a correlation was calculated between 
the concentrations of specific IgE antibodies to the ex-
tracts of  D. pteronyssinus and  farinae , resulting in a cor-
relation coefficient of 0.992, p < 0.0001.
 From 7 patients, sera were available for further testing 
of which 3 sera showed IgE reactivity to dot-blotted nDer 
p 1, and 2 others reacted with high-molecular weight 
components (>100 kDa) in nitrocellulose-blotted HDM 
extract when tested with  125 I-labeled anti-IgE in a RAST-
based assay (data not shown). The HDM extract-specific 
IgE levels of the 11 patients were <3.9 kUA/l ( table 2 ).
 Discussion 
 By means of the actually available HDM allergen com-
ponents (Der p 1, Der p 2, and Der p 10), it was not pos-
sible to diagnose HDM allergy in a number of patients 
when used alone. Research groups from central Europe, 
Africa, Brazil, and Australia have published different IgE 
reactivity patterns in HDM-allergic patients, demonstrat-
ing that there is no single major allergen component that 
can be used for diagnostic purposes alone worldwide  [3–
5, 14–17] . Therefore, the aim of this study was to analyze 










































C.L. 11 1 0 2 0 2 0 2 1.52 0.69 0.00 + – + M +
A.S.K. 21 3 2 0 0 2 1 3 1.44 0.35 0.00 – + + P +
O.C. 53 2 2 3 3 1 1 3 0.38 0.35 0.00 + n.a. + M –
S.H. 37 3 2 1 3 2 1 3 1.15 0.35 0.00 + + + P +
D.S. 18 1 2 1 2 3 3 3 0.37 0.39 0.35 – + + M +
G.R. 60 2 1 3 2 1 1 3 0.72 0.56 0.00 – + + P –
M.B. 27 n.a. n.a. n.a n.a. 3 0 3 2.99 0.59 1.60 n.a. n.a. + P +
K.L. 56 3 1 1 2 2 0 3 0.67 0.50 0.00 n.a. n.a. + M –
H.H. 27 n.a. n.a. n.a. n.a. 3 1 3 3.84 3.69 0.00 + – + M –
J.K.K. 23 n.a. n.a. n.a. n.a. 2 2 3 0.45 0.39 0.00 – + + M –
E.F. 27 1 0 0 0 2 2 3 1.40 1.32 0.00 – + + P –
A.K. 29 n.a. n.a. n.a. n.a. 1 1 3 0.46 0.40 0.00 – + + M –
S.R.S. 38 2 2 1 1 2 2 3 0.85 0.66 0.00 + + + P –
J.T. 56 2 2 1 1 2 2 3 0.74 0.68 0.00 – + + M –
H.W. 36 3 2 2 1 1 1 3 0.75 0.86 0.00 – + + M –
S.M. 29 0 1 1 0 1 1 3 1.41 1.61 0.00 – + + P –
Mean 34.25 1.92 1.42 1.33 1.25 1.88 1.19 2.94 1.20 0.84
SD 14.84 1.00 0.79 0.98 1.14 0.72 0.83 0.25 0.96 0.84
Max. 60.00 3.00 2.00 3.00 3.00 3.00 3.00 3.00 3.84 3.69
Min. 11.00 0.00 0.00 0.00 0.00 1.00 0.00 2.00 0.37 0.35
 Patients who had a positive result on the MeDALL chip (Der p 23) are shown in bold. Nasal symptoms (obstruction, rhinorrhea, sneezing, and itching) 
were semiquantitatively assessed on the day of the first visit: 0 = no impairment, 1 = mild impairment, 2 = moderate impairment, 3 = severe impairment. 
Skin prick test (SPT): 0 = wheal <3 mm, 1 = wheal 3 – 4 mm, 2 = wheal 4 – 5 mm, 3 = wheal 5 – 6 mm, 4 = wheal >6 mm. Nasal provocation test (NPT): de-
crease in rhinomanometry >40% at 150 Pa on the allergen-challenged side or symptom score >3, or decrease in rhinomanometry >20% at 150 Pa on the 
allergen-challenged side and symptom score >2. D. pter. = D. pteronyssinus; D. far. = D. farinae; M = monosensitized; P = polysensitized; n.a. = not available; 
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the reactivity profile of proven HDM-allergic patients 
which were tested negative for the commercially available 
allergens Der p 1, Der p 2, and Der p 10 with an experi-
mental allergen chip containing additional 10 HDM al-
lergen components. Special interest was focused on Der 
p 23 as Weghofer et al.  [11] showed in 347 patients a com-
parable prevalence of Der p 23 (74%) in comparison to 
Der p 1 and Der p 2 indicating the importance of this al-
lergen component as a new major HDM allergen. This 
fact is supported by latest research from Thailand where 
54% of 222 HDM-allergic patients displayed Der p 23-spe-
cific IgE responses  [18] . In the current study, 5 of 16 pa-
tients showed positive results for Der p 23 whereas all 
other allergen components including Der p 4, which 
showed a high prevalence in an aboriginal community in 
Australia   [19] , were tested negative. Symptoms of Der p 
23-positive patients did not differ from symptoms of pa-
tients who tested negative for this component. Der p 23 
therefore may help to clarify HDM allergy in nearly one 
third of the cases when until now commercially available 
HDM component testing leads to negative results in the 
catchment area of our hospital in southern Germany.
 Cross-reacting group 1 and group 2 allergens from  D. 
pteronyssinus and  farinae are well known  [20] . In all the 
16 patients, Der f 1 and Der f 2 as well as Der p 1 and Der 
p 2 showed negative results in immunoassay biochip test-
ing in spite of positive results for allergen extracts of  D. 
pteronyssinus and  farinae by FEIA. In patients tested neg-
ative for all HDM components, concentrations of IgE an-
tibodies against both allergen extracts correlated well, in-
dicating a cross-reacting allergen component which is not 
covered by the MeDALL chip so far. Chan et al.  [21]  were 
able to identify a new allergen component of  D. farinae 
(Der f 24), an ubiquinol-cytochrome c reductase binding 
protein originating from  Enterobacter species inhabiting 
the mite gut. The authors highlight the fact that the inter-
nal HDM body is host to more than 100 bacterial species, 
with a predominance of  Enterobacter species, and that al-
lergen components from their microbiome can be of im-
portance for HDM allergenicity and immunotherapy 
mechanisms. Although not proven yet, the results of 
Chan et al.  [21] might explain our findings for group 1 
and 2 allergens from  D. pteronyssinus and  farinae via re-
actions to bacterial allergen components which can be 
found in both allergen extracts.
 CCDs from plants and invertebrates are able to induce 
IgE production with cross-reacting properties  [22–24] . 
CCD sensitization is normally considered clinically irrel-
evant due to a poor activity in vivo but can serve as a dis-
turbing factor in specific IgE assays especially in patients 
allergic to plants and in patients with a  Hymenoptera ven-
om allergy  [25, 26] . Only 2 of 15 patients in the current 
study showed positive results for CCDs indicating that 
the good correlation between the allergen extracts of  D. 
pteronyssinus and  farinae is not caused by these cross-
reacting antibodies.
 Subcutaneously or sublingually applied allergen-spe-
cific immunotherapy represents the only disease-modi-
fying and allergen-specific approach with long-lasting 
effects. In contrast, symptomatic therapy is only able to 
decrease symptoms like nasal obstruction, rhinorrhea 
and itching but cannot influence the allergic immune re-
sponse itself. From this perspective, immunotherapy is 
superior to symptomatic therapy. In our study, 11 pa-
tients (11%) showed negative results for the previous 
HDM major allergens Der p 1 and Der p 2 but addition-
ally showed negative results for further 10 HDM aller-
gens when using the experimental MeDALL chip. Most 
companies in the market of HDM immunotherapy stan-
dardize their formulations to Der p 1, Der p 2, or Der f 1 
 [9, 10] . Analysis of HDM extracts from different manu-
facturers revealed varying allergen compositions and 
contents when examined for several  D. pteronyssinus al-
lergen components (Der p 1, 2, 5, 7, 10, and 21) by Casset 
et al.  [27] . Der p 1 and Der p 2 could be detected in all 
extracts, but high variations in concentrations were seen, 
whereas other components, e.g. Der p 21, were complete-
ly absent in many formulations. Consequently, patients 
with a proven allergy due to one of these two major al-
lergen components should benefit from therapy. But 
what should be done with patients not sensitized to the-
ses major components, showing sensitization to Der p 23 
or the HDM extract only? Are these patients suitable for 
immunotherapy with the actually available therapeutic 
solutions? These questions should be addressed in the 
future to improve clinical results of immunotherapy and 
to reduce treatment failure. Eleven of the 97 patients 
(11%) in our study showed a reactivity profile with none 
of 13 HDM allergen components in commercially avail-
able test platforms. As a consequence of these findings, 
molecular diagnostics for major allergen components 
should be mandatory before immunotherapy in HDM-
allergic patients. For diagnostic purposes, measurement 
of specific antibodies to HDM extracts is a safe and rou-
tine procedure. To optimize therapy outcome and to im-
prove reporting and comparability of clinical trials, it 
would be desirable to have more information about the 
content of major and minor allergen components in 
therapeutic solutions used in daily routine as well as in 
clinical trials.
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 Der p 23 is a new important HDM allergen which can 
help to clarify perennial allergic symptoms when the 
known major HDM allergen components Der p 1 and 
Der p 2 as well as Der p 10 were negative. Further research 
concerning prevalence and clinical relevance of Der p 23 
is needed to improve diagnostics and therapy of house 
dust mite allergy in the future. It is desirable to have Der 
p 23 commercially available for research purposes as well 
as in clinical routine.
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